Remote-onset alopecia areata attributed to ipilimumab

David R. Pearson, Karl Lewis, Theodore Alkousakis

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Ipilimumab is a fully humanized monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and one of a growing class of immunomodulatory therapies for melanoma. The most common toxicities are immune-related adverse effects (irAEs), which manifest most frequently in the skin as rash and pruritus. We report a case of alopecia areata (AA) attributed to ipilimumab that presented 1.5 years after treatment. Because CTLA-4 dysregulation has been increasingly linked to AA, the incidence of this irAE may increase following US Food and Drug Administration approval of a higher dose of ipilimumab for adjuvant treatment of stage III melanoma.

Original languageEnglish (US)
Pages (from-to)E25-E27
Issue number6
StatePublished - Dec 1 2019


Dive into the research topics of 'Remote-onset alopecia areata attributed to ipilimumab'. Together they form a unique fingerprint.

Cite this